Conditions: Diabetic Kidney Disease
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 52
Healthy volunteers: yes

Brief summary:
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.

Detailed description:

Arms:
arm 1: Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1. arm 2: Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1. arm 3: Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.

Interventions: intervention 1: Selonsertib
Intervention descriptions: intervention 1: 6 mg tablets administered orally in fed state

Protocol document: